EMA Authorised: Aranesp (darbepoetin alfa) — Amgen Europe B.V.

View source ↗

Summary

EMA authorised Aranesp (darbepoetin alfa) for anemia associated with cancer and chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Status: Authorised. Therapeutic area: Anemia;Cancer;Kidney Failure, Chronic. MAH: Amgen Europe B.V.. Decision date: 27/11/2025